IDYA logo

IDEAYA Biosciences Inc. (IDYA)

$27.40

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on IDYA

Market cap

$2.65B

EPS

-4.46

P/E ratio

--

Price to sales

14.88

Dividend yield

--

Beta

0.081021

Price on IDYA

Previous close

$30.36

Today's open

$30.42

Day's range

$26.68 - $31.85

52 week range

$26.68 - $42.68

Profile about IDYA

CEO

Yujiro S. Hata

Employees

145

Headquarters

South San Francisco, CA

Exchange

Nasdaq Global Select

Shares outstanding

96694575

Issue type

Common Stock

IDYA industries and sectors

Healthcare

Biotechnology & Life Sciences

News on IDYA

Ideaya Biosciences: Staying Bullish On Darovasertib NDA Submission And More

I maintain a 'Strong Buy' on Ideaya Biosciences, Inc.: the darovasertib NDA submission is complete, while IDE849 offers multiple registrational opportunities. Darovasertib plus crizotinib targets HLA-A*02:01-negative metastatic uveal melanoma; phase 3 OptimUM-011 expands the program into adjuvant treatment. IDE849's FDA-aligned single-arm GEP-NEC cohort could support Accelerated Approval; two additional registrational studies are planned.

news source

Seeking Alpha • 16 hours ago

news preview

IDEAYA Biosciences, Inc. (IDYA) Presents at UBS Global Biopharma Conference 2026 Transcript

IDEAYA Biosciences, Inc. (IDYA) Presents at UBS Global Biopharma Conference 2026 Transcript

news source

Seeking Alpha • Nov 16, 2026

news preview

IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas

Single-arm extension cohort of approximately 90 refractory GEP-NEC patients to support potential accelerated approval, with ORR by BICR as the primary endpoint Randomized Phase 3 trial in multiple refractory NEC subtypes, including GEP-NEC and LC-NEC, is planned to support full approval, with OS as the primary endpoint IDE849 has demonstrated a 52.6% ORR (10/19), median PFS of 7.0 months, and an estimated 9-month OS rate of 82.4% in 2L+ NEC Global Phase 1/2 trial of IDE849 has shown a Grade ≥3 TRAE rate of 5% (1/20) and 22.2% (4/18) at the 2.4 mg/kg and 3.5 mg/kg expansion doses, respectively IDEAYA is targeting to initiate two randomized Phase 3 registrational trials in the refractory NEC and post-Imdelltra ES-SCLC settings, and a potential registration-enabling single-arm extension cohort in refractory GEP-NEC, by the end of 2026 SOUTH SAN FRANCISCO, Calif., Nov. 16, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization of transformative therapies to address unmet medical needs in cancer, today announced its registrational strategy for IDE849, a potential best-in-class delta-like ligand 3 (DLL3)-targeting Topo-I-payload antibody drug conjugate (ADC), in previously treated (2L+) neuroendocrine carcinomas (NEC).

news source

PRNewsWire • Nov 16, 2026

news preview

IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors

Development candidate demonstrates encouraging preclinical activity in CDKN2A-deficienct tumor models as a monotherapy and in combination with inhibitors of RAS and MTAP, including IDEAYA's proprietary Phase 1 PRMT5 inhibitor IDE892 CDKN2A-deficiency is a common tumor suppressor loss prevalent in ~10-15% of all solid tumors, including ~70% of pancreatic cancer IDE101's preclinical profile, including combination results with inhibitors of PRMT5 and pan-RAS, will be summarized at IDEAYA's London R&D Day IND-enabling studies underway to support an IND filing in H1 2027 SOUTH SAN FRANCISCO, Calif., Nov. 15, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced development candidate nomination of IDE101, a potential first-in-class dual cyclin-dependent kinase (CDK) inhibitor designed to address the loss of CDKN2A-mediated tumor suppressor function in cancer.

news source

PRNewsWire • Nov 15, 2026

news preview

IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events

SOUTH SAN FRANCISCO, Calif., Nov. 4, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced its participation in the upcoming investor relations events.

news source

PRNewsWire • Nov 4, 2026

news preview

IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update

Data presented at ESMO 2026 collectively supports the potential of darovasertib to become a foundational new therapy across the treatment journey of uveal melanoma in both primary and metastatic disease, irrespective of HLA-A*02:01 allele status or line of therapy Completed NDA submission in Q3'26 to support the potential U.S. approval of darovasertib plus crizotinib in metastatic uveal melanoma Updated data from Hengrui-sponsored Phase 1 trial of IDE849 (DLL3 TOP1 ADC) presented at ESMO 2026 demonstrates robust anti-tumor activity and encouraging survival benefit in relapsed small cell lung cancer (SCLC) and neuroendocrine carcinomas (NEC); initial data from IDEAYA-sponsored global Phase 1/2 trial expected by the end of 2026 / early 2027 IDEAYA R&D Day scheduled for November 16th to highlight preclinical data supporting rational combinations that exploit MTAP/CDKN2A deficiency in KRAS-mutant cancers $1.15 billion in cash, cash equivalents and marketable securities as of September 30, 2026; cash runway guidance into 2030 remains unchanged based on current operating plan SOUTH SAN FRANCISCO, Calif., Nov. 3, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization of targeted therapeutics, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.

news source

PRNewsWire • Nov 3, 2026

news preview

IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Tops Revenue Estimates

IDEAYA Biosciences, Inc. (IDYA) came out with a quarterly loss of $1.22 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to earnings of $1.33 per share a year ago.

news source

Zacks Investment Research • Nov 3, 2026

news preview

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization of targeted therapeutics, today announced that, on October 29, 2026, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 99,600 shares of the Company's common stock to four newly hired employees.

news source

PRNewsWire • Oct 30, 2026

news preview

IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

IDEAYA Biosciences (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

news source

Zacks Investment Research • Oct 27, 2026

news preview

IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas

17.4-month median OS in 2L SCLC (n=51) and 14.7-month median OS in 2L + ≥3L SCLC (n=101) 72.5% (37/51) ORR and 60.8% (31/51) cORR in 2L SCLC with 6.9-month median PFS; 68.3% (69/101) ORR and 54.5% (55/101) cORR in 2L + ≥3L SCLC with 6.8-month median PFS 76.9% (20/26) ORR and 65.4% (17/26) cORR in SCLC patients with brain metastases Efficacy observed in NECs, with 52.6% (10/19) ORR, 36.8% (7/19) cORR, 7.0-month median PFS and an 82.4% nine-month OS rate Grade ≥3 TRAE of 33.3% at the 2.4 mg/kg expansion dose. 2.5% treatment-related discontinuation rate and 0.8% Grade ≥3 ILD rate observed across the study (n=122) In IDEAYA's separate IDE849 global clinical study at the 2.4 mg/kg and 3.5 mg/kg expansion doses a Grade ≥3 TRAE rate of 5% (1/20) and 22.2% (4/18) have been observed, respectively Following successful Type C meetings with the U.S. FDA, IDEAYA is targeting to initiate two Phase 3 registrational trials with IDE849 in ES-SCLC and NEC.

news source

PRNewsWire • Oct 23, 2026

news preview

¹ Disclosures

Get started with M1

Invest in IDEAYA Biosciences Inc.

Open an M1 investment account to buy and sell IDEAYA Biosciences Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in IDYA on M1